Abera Bioscience awarded 1 Million SEK grant from Vinnova for further development of nasal pneumococcal vaccine
Abera Bioscience AB (“Abera” or “the Company”) has been awarded a 1 million SEK grant from Vinnova to advance the development of its innovative pneumococcal